August 27, 2024 02:44 PM EDT

Biopharma companies, BARDA call for more clarity on FDA's new platform tech proposal

Zachary Brennan

Senior Editor

Following the FDA’s May release of long-awaited draft guidance explaining how companies can win designations for certain cell and gene therapy “platform” technologies, companies like …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biopharma companies, BARDA call for more clarity on FDA's new platform tech proposal

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

Bio­phar­ma com­pa­nies, BAR­DA call for more clar­i­ty on FDA's new plat­form tech pro­pos­al

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Biopharma companies, BARDA call for more clarity on FDA's new platform tech proposal